Developer docs
API playgroundTry for free, no card

Search company profiles

Vectorious Medical Technologies

Full company profile

uuid0000guh

Namestring
Vectorious Medical Technologies
Legal namestring
Vectorious
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Vectorious Medical Technologies is an Israeli medical device company founded in 2011 and headquartered in Tel Aviv, developing the V-LAP System, a wireless implantable sensor platform for continuous left atrial pressure (LAP) monitoring in heart failure patients. The platform combines a miniature in-heart sensor with wireless power harvesting technology (eliminating the need for batteries or wires), proprietary signal processing and data mining algorithms, a mobile patient self-management application enabling twice-daily self-measurements, and cloud-based physician dashboards. The company has conducted multiple clinical trials (VECTOR-HF I, II, IIa, IIb) and accumulated 65,940+ patient-days of LAP data, described as the world's largest such dataset as of May 2026. Peer-reviewed publications have appeared in the Journal of Cardiac Failure and European Journal of Heart Failure, with conference participation at ESC, TCT, HFSA, and CSI events.

The intended business model is a traditional medical device commercial motion: physician-prescribed implant sales targeting cardiologists and heart failure specialists through hospital systems following regulatory approval, with the hardware (implant) as the primary revenue stream and ongoing monitoring platform as a recurring value layer. As of the data collection date, the V-LAP System remains an investigational device not approved for clinical use in any geography, with no disclosed pricing. In Q3 2025, Edwards Lifesciences completed a full acquisition of Vectorious for $497 million, making it a wholly-owned subsidiary within Edwards' broader cardiovascular portfolio. Prior to acquisition, the company had received EU Horizon 2020 grant funding (grant agreement No. 811765) and venture capital from Fresenius Medical Care, Broadview Ventures, GEOC, RAD BioMed Accelerator, Cleveland Clinic, Israel Innovation Authority, and Champel Capital. The company was co-founded by Eyal Orion, who serves as Chairman of the Board.

Short descriptiontext

Vectorious Medical Technologies develops the V-LAP System, a wireless implantable left atrial pressure sensor for continuous heart failure monitoring, enabling real-time physician-guided medication adjustment. Now a subsidiary of Edwards Lifesciences following its Q3 2025 $497 million acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable cardiac sensors, heart failure monitoring, left atrial pressure, wireless medical devices, cardiac remote monitoring
Industry4 codes
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Implantable Cardiac Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Implantable Cardiac Device Sales
TypeHardware Sales
Description

Vectorious Medical Technologies is developing the V-LAP system, an implantable left atrial pressure sensor for heart failure monitoring. Following regulatory approval, the company will generate revenue through sales of the implantable device and associated monitoring platform. The technology was acquired by Edwards Lifesciences for $497 million in Q3 2025, indicating commercial development is anticipated.

dealforma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vectorious Medical Technologies develops the V-LAP System, an investigational wireless implantable sensor platform that continuously monitors Left Atrial Pressure (LAP) in heart failure patients. The system combines a miniature battery-free and wire-free sensor implanted in the heart, a mobile patient self-management application for two-minute twice-daily measurements, and cloud-based web clients for physician monitoring with real-time alerts and medication adjustment guidance. The platform is supported by the VECTOR-HF clinical program generating the world's largest LAP dataset of 65,940+ patient-days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 65,940 days of patient LAP data - largest LAP data set in the world
Product overview1 text field

Vectorious Medical Technologies offers the V-LAP System, a single unified implantable device platform designed for continuous heart failure monitoring. The platform consists of a wireless miniature sensor implanted in the heart, a companion mobile patient app for self-management and medication guidance, and cloud-based web clients for physician monitoring. The system captures the world's largest Left Atrial Pressure (LAP) dataset and uses proprietary algorithms to enable real-time medication adjustment recommendations and automatic physician alerts. The V-LAP System is currently an investigational device not approved for clinical use. Clinical validation is ongoing through the VECTOR-HF clinical study program.

Product and service1 record
1V-LAP System
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Abbott Laboratories (CardioMEMS HF System)
TypeDirect peer
Description

Abbott's CardioMEMS HF System is the only commercially approved implantable wireless pulmonary artery pressure sensor for heart failure monitoring — the closest direct competitor to Vectorious's V-LAP. Both target continuous remote hemodynamic monitoring of HF patients with similar value propositions around reducing hospitalizations.

TypeBroad incumbent
Description

Edwards Lifesciences is Vectorious's strategic acquirer (Q3 2025, $497M) and parent company. Edwards is a global leader in structural heart, heart failure, and critical care with a commercial platform that Vectorious now plugs into; it represents the incumbent whose portfolio V-LAP complements.

TypeDirect peer
Description

Endotronix developed the Cordella PA pressure sensor system, a wireless implantable pulmonary artery pressure monitor for HF management. It is a direct competitor in the implantable remote hemodynamic monitoring category, pursuing similar use cases and clinical evidence strategy as Vectorious.

TypeBroad incumbent
Description

Medtronic is a global cardiovascular device incumbent with a broad portfolio spanning cardiac rhythm, heart failure diagnostics (e.g., LINQ ICM, TriageHF), and remote monitoring infrastructure. As a large diversified medtech, it competes broadly with the Vectorious/Edwards HF monitoring portfolio.

TypeBroad incumbent
Description

Boston Scientific is a diversified cardiovascular device player with growing presence in heart failure (e.g., Cardiac Diagnostics & Services, BodyGuardian remote monitoring). It overlaps with Vectorious's HF monitoring category as part of a broader portfolio.

TypeEmerging player
Description

V-Wave developed an interatrial shunt device for heart failure with preserved ejection fraction (HFpEF). While its mechanism is different (mechanical vs. sensing), it targets the same HF patient population and represents an emerging adjunctive HF therapy that could be combined with or compete against Vectorious's monitoring approach.

TypeBroad incumbent
Description

BIOTRONIK is a European cardiovascular device company offering implantable cardiac monitors (BIOMONITOR), CRM devices, and remote monitoring (Home Monitoring) services. It competes in cardiac rhythm and remote monitoring adjacent to Vectorious's HF monitoring focus.

TypeEmerging player
Description

iRhythm's Zio long-term cardiac monitoring patch and AI-based arrhythmia detection platform competes in ambulatory cardiac monitoring and digital cardiology. It addresses a related but adjacent use case (rhythm vs. pressure) for continuous cardiac insight outside the clinic.

TypeEmerging player
Description

AliveCor (KardiaMobile) provides consumer and clinical ECG-based remote cardiac monitoring. It addresses lower-acuity outpatient monitoring and represents a non-implantable, lower-cost alternative positioned upstream of Vectorious's invasive implantable solution.

TypeEmerging player
Description

Procyrion is developing the Aortix percutaneous heart pump for cardiogenic shock and decompensated HF. While therapy-focused rather than monitoring, it addresses acute HF care in the same patient population Vectorious targets and represents an emerging interventional HF therapy player.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vectorious Medical Technologies

Implantable Cardiac Devicesvectoriousmedtech.com

Vectorious Medical Technologies develops the V-LAP System, a wireless implantable left atrial pressure sensor for continuous heart failure monitoring, enabling real-time physician-guided medication adjustment. Now a subsidiary of Edwards Lifesciences following its Q3 2025 $497 million acquisition.

What Vectorious Medical Technologies does

Vectorious Medical Technologies is an Israeli medical device company founded in 2011 and headquartered in Tel Aviv, developing the V-LAP System, a wireless implantable sensor platform for continuous left atrial pressure (LAP) monitoring in heart failure patients. The platform combines a miniature in-heart sensor with wireless power harvesting technology (eliminating the need for batteries or wires), proprietary signal processing and data mining algorithms, a mobile patient self-management application enabling twice-daily self-measurements, and cloud-based physician dashboards. The company has conducted multiple clinical trials (VECTOR-HF I, II, IIa, IIb) and accumulated 65,940+ patient-days of LAP data, described as the world's largest such dataset as of May 2026. Peer-reviewed publications have appeared in the Journal of Cardiac Failure and European Journal of Heart Failure, with conference participation at ESC, TCT, HFSA, and CSI events.

The intended business model is a traditional medical device commercial motion: physician-prescribed implant sales targeting cardiologists and heart failure specialists through hospital systems following regulatory approval, with the hardware (implant) as the primary revenue stream and ongoing monitoring platform as a recurring value layer. As of the data collection date, the V-LAP System remains an investigational device not approved for clinical use in any geography, with no disclosed pricing. In Q3 2025, Edwards Lifesciences completed a full acquisition of Vectorious for $497 million, making it a wholly-owned subsidiary within Edwards' broader cardiovascular portfolio. Prior to acquisition, the company had received EU Horizon 2020 grant funding (grant agreement No. 811765) and venture capital from Fresenius Medical Care, Broadview Ventures, GEOC, RAD BioMed Accelerator, Cleveland Clinic, Israel Innovation Authority, and Champel Capital. The company was co-founded by Eyal Orion, who serves as Chairman of the Board.

Vectorious Medical Technologies firmographics

Firmographics
Name
Vectorious Medical Technologies
Legal name
Vectorious
Website
https://vectoriousmedtech.com
Company type
Private
Founded year
2011
Operating status
Acquired
Headcount range
101–250 employees
Short description
Vectorious Medical Technologies develops the V-LAP System, a wireless implantable left atrial pressure sensor for continuous heart failure monitoring, enabling real-time physician-guided medication adjustment. Now a subsidiary of Edwards Lifesciences following its Q3 2025 $497 million acquisition.
Ownership category
akta.pro rank

Vectorious Medical Technologies industry classification

Industry
Product category
Implantable Cardiac Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Implantable cardiac sensors
  • Heart failure monitoring
  • Left atrial pressure
  • Wireless medical devices
  • Cardiac remote monitoring

Where Vectorious Medical Technologies is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Vectorious Medical Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Implantable Cardiac Device Sales: Vectorious Medical Technologies is developing the V-LAP system, an implantable left atrial pressure sensor for heart failure monitoring. Following regulatory approval, the company will generate revenue through sales of the implantable device and associated monitoring platform. The technology was acquired by Edwards Lifesciences for $497 million in Q3 2025, indicating commercial development is anticipated.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Vectorious Medical Technologies product offering

Product offering

Core offering

Vectorious Medical Technologies develops the V-LAP System, an investigational wireless implantable sensor platform that continuously monitors Left Atrial Pressure (LAP) in heart failure patients. The system combines a miniature battery-free and wire-free sensor implanted in the heart, a mobile patient self-management application for two-minute twice-daily measurements, and cloud-based web clients for physician monitoring with real-time alerts and medication adjustment guidance. The platform is supported by the VECTOR-HF clinical program generating the world's largest LAP dataset of 65,940+ patient-days.

Product overview

Vectorious Medical Technologies offers the V-LAP System, a single unified implantable device platform designed for continuous heart failure monitoring. The platform consists of a wireless miniature sensor implanted in the heart, a companion mobile patient app for self-management and medication guidance, and cloud-based web clients for physician monitoring. The system captures the world's largest Left Atrial Pressure (LAP) dataset and uses proprietary algorithms to enable real-time medication adjustment recommendations and automatic physician alerts. The V-LAP System is currently an investigational device not approved for clinical use. Clinical validation is ongoing through the VECTOR-HF clinical study program.

Differentiator

Problem solved

Functional benefit

Products and services

  • V-LAP System

Quantifiable outcome

  • 65,940 days of patient LAP data - largest LAP data set in the world

Companies that use Vectorious Medical Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

Vectorious Medical Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Vectorious Medical Technologies partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Vectorious Medical Technologies competitors and assessment

Company assessment

Direct peers

  • Abbott Laboratories (CardioMEMS HF System): Abbott's CardioMEMS HF System is the only commercially approved implantable wireless pulmonary artery pressure sensor for heart failure monitoring — the closest direct competitor to Vectorious's V-LAP. Both target continuous remote hemodynamic monitoring of HF patients with similar value propositions around reducing hospitalizations.
  • Endotronix: Endotronix developed the Cordella PA pressure sensor system, a wireless implantable pulmonary artery pressure monitor for HF management. It is a direct competitor in the implantable remote hemodynamic monitoring category, pursuing similar use cases and clinical evidence strategy as Vectorious.

Broad incumbents

  • Edwards Lifesciences: Edwards Lifesciences is Vectorious's strategic acquirer (Q3 2025, $497M) and parent company. Edwards is a global leader in structural heart, heart failure, and critical care with a commercial platform that Vectorious now plugs into; it represents the incumbent whose portfolio V-LAP complements.
  • Medtronic: Medtronic is a global cardiovascular device incumbent with a broad portfolio spanning cardiac rhythm, heart failure diagnostics (e.g., LINQ ICM, TriageHF), and remote monitoring infrastructure. As a large diversified medtech, it competes broadly with the Vectorious/Edwards HF monitoring portfolio.
  • Boston Scientific: Boston Scientific is a diversified cardiovascular device player with growing presence in heart failure (e.g., Cardiac Diagnostics & Services, BodyGuardian remote monitoring). It overlaps with Vectorious's HF monitoring category as part of a broader portfolio.
  • BIOTRONIK: BIOTRONIK is a European cardiovascular device company offering implantable cardiac monitors (BIOMONITOR), CRM devices, and remote monitoring (Home Monitoring) services. It competes in cardiac rhythm and remote monitoring adjacent to Vectorious's HF monitoring focus.

Emerging players

  • V-Wave: V-Wave developed an interatrial shunt device for heart failure with preserved ejection fraction (HFpEF). While its mechanism is different (mechanical vs. sensing), it targets the same HF patient population and represents an emerging adjunctive HF therapy that could be combined with or compete against Vectorious's monitoring approach.
  • iRhythm Technologies: iRhythm's Zio long-term cardiac monitoring patch and AI-based arrhythmia detection platform competes in ambulatory cardiac monitoring and digital cardiology. It addresses a related but adjacent use case (rhythm vs. pressure) for continuous cardiac insight outside the clinic.
  • AliveCor: AliveCor (KardiaMobile) provides consumer and clinical ECG-based remote cardiac monitoring. It addresses lower-acuity outpatient monitoring and represents a non-implantable, lower-cost alternative positioned upstream of Vectorious's invasive implantable solution.
  • Procyrion: Procyrion is developing the Aortix percutaneous heart pump for cardiogenic shock and decompensated HF. While therapy-focused rather than monitoring, it addresses acute HF care in the same patient population Vectorious targets and represents an emerging interventional HF therapy player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Vectorious Medical Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vectorious Medical Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Vectorious Medical Technologies funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vectorious Medical Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vectorious Medical Technologies

What does Vectorious Medical Technologies do?

Vectorious Medical Technologies develops the V-LAP System, an investigational wireless implantable sensor platform that continuously monitors Left Atrial Pressure (LAP) in heart failure patients. The system combines a miniature battery-free and wire-free sensor implanted in the heart, a mobile patient self-management application for two-minute twice-daily measurements, and cloud-based web clients for physician monitoring with real-time alerts and medication adjustment guidance. The platform is supported by the VECTOR-HF clinical program generating the world's largest LAP dataset of 65,940+ patient-days.

Is Vectorious Medical Technologies a public or private company?

Vectorious Medical Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Vectorious Medical Technologies founded?

Vectorious Medical Technologies was founded in 2011. It employs 101 to 250 people.

Where is Vectorious Medical Technologies based?

Vectorious Medical Technologies is headquartered in Tel Aviv, Israel, in the Middle East region.

How does Vectorious Medical Technologies make money?

One revenue line is on record: implantable Cardiac Device Sales.

Who are Vectorious Medical Technologies's main competitors?

Direct peers on record are Abbott Laboratories (CardioMEMS HF System) and Endotronix. Broad incumbents are Edwards Lifesciences, Medtronic, Boston Scientific and BIOTRONIK. Emerging players are V-Wave, iRhythm Technologies, AliveCor and Procyrion.

Does Vectorious Medical Technologies have an API?

No public API is recorded for Vectorious Medical Technologies.

What industry is Vectorious Medical Technologies in?

Vectorious Medical Technologies's product category is Implantable Cardiac Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DealformaCardiovascular R&D Partnerships, M&A and Venture Funding by TechCardiovascular deal activity in Q3 2025 drew over $10 billion across R&D partnerships, M&A, and venture funding, with biologics dominating R&D at $7 billion across 3 deals. Major M&A included Novartis' $1.4 billion acquisition of Tourmaline Bio, Edwards Lifesciences' $497 million purchase of Vectorious Medical, and MannKind's $360 million acquisition of scPharmaceuticals. Venture funding totaled $554 million, led by Kardium Inc.'s $250 million raise for its atrial fibrillation Globe Pulsed Field System and Baraya Health's $124 million Series B for extended care expansion in Saudi Arabia.AInvestEdwards Lifesciences Acquires Israeli Medtech Firm Vectorious Medical for $497m ValuationEdwards Lifesciences completed its acquisition of Israeli medtech firm Vectorious Medical, buying the remaining 48% stake for $497 million. The company previously held a 52% stake since 2023. Vectorious develops battery-free sensors for heart disease management, and the acquisition aims to integrate this technology into Edwards' product offerings.PR NewswireV-LAP Allows Heart Failure Patients to Self-Adjust Medication: Vectorious Reports Promising Findings From its Pilot Study at the THT meetingVectorious Medical Technologies presented interim results from its V-LAP sensor pilot study at the THT 2023 conference in Boston, showing that 89.1% of the 3,504 follow-up days required only patient self-management to maintain optimal Left Atrial Pressure, with physician intervention needed just 10.9% of the time. The study of 13 heart failure patients found zero heart failure-related hospitalizations during the study period compared to 0.69 per patient prior, along with significant improvements in 6-minute walk distance (187m to 325m) and quality-of-life scores. Researchers stated larger randomized controlled studies are required to confirm the effectiveness of this physician-directed, patient self-management approach.PR NewswireGlobal $2.1 Bn Implantable Loop Recorders Market Outlook, 2026 - Key Players are Medtronic, Abbott Labs, Boston Scientific, Biotronik, Angel Medical Systems, and Vectorious Medical TechnologiesResearch and Markets released a market research report projecting the global implantable loop recorders market to reach $2.1 billion by 2026, growing at a CAGR of 11.9% during the forecast period, driven by technological advances and the development of smarter devices with Bluetooth and Wi-Fi connectivity. The report profiles key industry players including Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, Angel Medical Systems, Inc., and Vectorious Medical Technologies Ltd., noting recent FDA approvals for Medtronic's LINQ II insertable cardiac monitor and Boston Scientific's LUX-Dx Insertable Cardiac Monitor System in mid-2020.BusinessCloudWorld-first heart implant computer helps chronic disease patientsVectorious developed a wireless heart implant that sends pressure readings to clinicians via a daily belt, enabling home-based medication adjustments for chronic heart disease patients. The company has 13 patients in trials, plans to expand to 30, and seeks FDA clearance by next year. It aims to improve quality of life and lifespan through precise treatment.GlobesKidney disease co Fresenius expands Israeli activitiesFresenius Medical Care is expanding its Israeli activities, investing over €1 million in a digital nephrology patient database and a $2 million investment in Vectorious Medical Technologies. The company has operated in Israel since 2016, owning 30 institutes treating 2,300 kidney patients. It plans to connect its data with health funds and invest in clinical research.GlobesIsraeli heart monitoring co Vectorious raises $9.5mVectorious Medical Technologies raised $9.5 million in a Series B round led by Broadview Ventures and GEOC, with a $2.2 million EU grant. The funds will support workforce expansion and clinical trials for European marketing approval. The company's V-LAP device monitors left-atrial activity.FinSMEsVectorious Medical Technologies Closes $5M FinancingVectorious Medical Technologies, a Tel Aviv-based medical device company, closed a $5M financing round. Backers include RadBioMed, private investors, and the Cleveland Clinic's Global Cardiovascular Innovation Center. The company will use the funds to initiate first-in-human trials for its cardiac monitoring system.